-
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales…
-
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 22, 2026 /PRNewswire/ — Pictor Holdings Inc., a global targeted proteomic platform company, today highlighted the publication of an independent peer-reviewed study conducted by researchers at Texas A&M University and published…
-
2026 World Cup: Global Health Leaders Demand FIFA End its Coca-Cola Partnership – Vital Strategies
NEW YORK, June 4, 2026 /PRNewswire/ — A formidable coalition of global health experts and advocates is demanding FIFA commit to ending its partnership with Coca-Cola by 2030. The Kick Big Soda Out movement first targeted FIFA during the 2025 Club World Cup in the United States—where campaigners accused Coca-Cola of sportswashing its health and environmental…
-
Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters
The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2, 2026 /PRNewswire/ — As laboratories increasingly seek faster, more cost-efficient alternatives to legacy single-analyte testing, demand for scalable multi-analyte proteomic workflows is…
-
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue IHC/FISH in EGFR-mutated NSCLC following progression on first-line targeted therapy (AUC=0.97) Baseline and longitudinal profiling in METex14 skipping NSCLC identified biology associated with therapeutic…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.